Back to Top

Ask about this Application

Application

Recombinant RabMAb®: Reliable antibodies for reproducible results

Abcam

Jan 28, 2022

Abstract

Poorly characterized antibodies often fail to provide consistent, reproducible results, thereby wasting materials, researcher time, and money. Compared to traditional polyclonal and monoclonal antibodies, recombinant antibodies exhibit very little batch-to-batch variability, providing scientists with highly reproducible results. In this white paper, we will showcase the reproducibility of recombinant antibodies by assessing the batch-to-batch consistency of the recombinant RabMab anti-PD-L1 antibody [28-8] (ab205921) across various applications, including IHC, ICC, flow cytometry, and western blot. Our results demonstrate high reproducibility between different batches of the recombinant anti-PD-L1 antibody tested in four different applications (IHC, ICC, flow cytometry, and western blot). Batch-to-batch reproducibility of recombinant antibodies overcomes the need for extensive downstream standardization assays saving time, cost, and/or resources. Consistency in the batch performance of recombinant antibodies ensures the longevity and reproducibility of research results generated with these reagents.


Application File

reproducibility-recombinant-antibodies-white-paper.pdf

Comments

Be the first to comment.

Submit a Comment

First Name *

Last Name *

Email *

Comments *

By submitting this form, you agree to the Genetic Engineering & Biotechnology News (GEN) privacy policy.

Premier Sponsor
Abcam